View Press Releases
Rho Experts to Present at 5th Annual Gene Therapy for Rare Disorders Conference
Rho Experts to Present at
5th Annual Gene Therapy for Rare Disorders Conference
Presentation will discuss key components to consider when designing and executing gene therapy nonclinical studies to enable clinical studies
WHAT: Rho, a global full-service contract research organization (CRO), is sharing its drug development success and expertise in gene therapy research during the 5th Annual Gene Therapy for Rare Disorders Conference, taking place in Boston, Massachusetts from March 7-10.
Rho’s Associate Director of Regulatory Strategy, Joseph Watson, Senior Director of Nonclinical Development, Brenda Faiola, and Research Scientist Kelsey Behrens will be giving a presentation titled, “Nonclinical Considerations to Enable a Successful Clinical Program.” The March 9 presentation at 2:00 p.m. will discuss key design and execution components, for nonclinical studies, necessary to enable clinical studies. The following items will be addressed:
ü Considerations for gene therapy programs regarding animal models, dose selection, and delivery device compatibility
ü Lessons Rho has learned in interacting with the FDA across various gene therapy programs
ü Gene therapy approval examples that highlight key nonclinical considerations
During the conference, the Rho team is exhibiting at booth 29 and will be available to answer any questions.
WHO: Joseph Watson, Ph.D., Associate Director, Regulatory Strategy, Rho
Brenda Faiola, Ph.D., DABT, Senior Director, Nonclinical Development, Rho
Kelsey Behrens, Ph.D., Research Scientist, Rho
WHEN: March 7-10, 2022
WHERE: Hynes Convention Center
900 Boylston St
Boston, MA 02115
MEDIA CONTACT:
Kelly Maicon
Largemouth Communications
(919) 741-9784; kmaicon@largemouthpr.com
ABOUT:
Rho is a global, privately held contract research organization (CRO) headquartered in Research Triangle Park, a biotech hub in North Carolina, US. Rho provides a full range of drug development services, from program strategy through to clinical trials and marketing applications. For more than 36 years, Rho has been a trusted partner to some of the most innovative pharmaceutical, biotechnology and medical device companies as well as academic and government organizations. Dedicated to service excellence and cross-functional collaboration, Rho’s therapeutic expertise, employee focus and commitment to strong site relationships change what it means to work with a CRO – accelerating time to market, maximizing ROI, and delivering consistent, smarter and more efficient programs. Experience Rho by following the company on Facebook, LinkedIn, Twitter, and Instagram.
###